Roluperidone also failed a phase 3 trial in 2020 but subsequently showed evidence that it may be able to target the negative symptoms of schizophrenia – such as apathy and social withdrawal ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.